First Time Loading...
I

Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 68.8 USD -2.19% Market Closed
Updated: May 4, 2024

Intra-Cellular Therapies Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Revenue
$464.4m
CAGR 3-Years
173%
CAGR 5-Years
N/A
CAGR 10-Years
67%
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Intra-Cellular Therapies Inc
Revenue Breakdown

Breakdown by Geography
Intra-Cellular Therapies Inc

Not Available

Breakdown by Segments
Intra-Cellular Therapies Inc

Total Revenue: 464.4m USD
100%
Product Sales, Net: 462.2m USD
99.5%
Grant Revenue: 2.2m USD
0.5%

See Also

What is Intra-Cellular Therapies Inc's Revenue?
Revenue
464.4m USD

Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Revenue amounts to 464.4m USD.

What is Intra-Cellular Therapies Inc's Revenue growth rate?
Revenue CAGR 10Y
67%

Over the last year, the Revenue growth was 86%. The average annual Revenue growth rates for Intra-Cellular Therapies Inc have been 173% over the past three years , and 67% over the past ten years .